Showing results (31-40 of 759) with videos related to
Sort By:
Pageof 76
BMC Biology|November 1, 2011
Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130CasDharminder Chauhan, Kenneth C AndersonInternational Journal of Hematology|September 2, 2011
Novel therapies in MM: from the aspect of preclinical studiesTeru Hideshima, Kenneth C AndersonBlood|October 9, 2004
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implicationsKlaus Podar, Kenneth C AndersonClinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2006
Synopsis of a roundtable on validating novel therapeutics for multiple myelomaWilliam Dalton, Kenneth C AndersonInternational Journal of Hematology|March 12, 2013
Histone deacetylase inhibitors in the treatment for multiple myelomaTeru Hideshima, Kenneth C AndersonCurrent Opinion in Oncology|November 1, 2002
Thalidomide and immunomodulatory drugs as cancer therapyNoopur Raje, Kenneth C AndersonCell Cycle (Georgetown, Tex.)|April 21, 2010
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathwaysKlaus Podar, Kenneth C AndersonSeminars in Hematology|June 26, 2012
Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studiesTeru Hideshima, Kenneth C AndersonCancer Letters|February 14, 2006
Caveolin-1 as a potential new therapeutic target in multiple myelomaKlaus Podar, Kenneth C AndersonNature Clinical Practice. Oncology|November 3, 2005
Drug insight: thalidomide as a treatment for multiple myelomaShaji Kumar, Kenneth C AndersonPageof 76